Clinical trials: First-Episode Psychosis
Impaired Insight
Study on Deep Transcranial Magnetic Stimulation for Enhancing Insight
Impaired insight is a key factor in the conversion of high-risk individuals to schizophrenia, but there is a lack of targeted interventions.
- Trial name
- NCT06831877
- Testing
- active-dTMS
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Trial name
- PAFIP2_nc1Y (NCT02534363)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Psychosis, First Episode Psychosis
Feasibility of an Early Detection Program for Early Psychosis on a College Campus
The objective of the proposed study is to determine the feasibility of an Early Detection program that aims to: (i) identify college students at clinical high risk (CHR) of psychosis or with first episode psychosis (FEP), and…
- Conditions
- Psychosis, First Episode Psychosis, Clinical High Risk for Psychosis
- Trial name
- NCT03983421
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Schizophrenia, Psychotic Disorders
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis
The selection of antipsychotic in early stages of the illness is mainly determined by its clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug treatment for individuals suffering from…
- Trial name
- PAFIP2 (NCT02305823)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
First Episode Psychosis
Efficacy and Safety With Ziprasidone in First-episode Psychosis
The aim of the study is to investigate the efficacy and safety of ziprasidone in patients with first episode psychosis.
- Trial name
- NCT01157559
- Testing
- Ziprasidone
- Where
- 3 sites in South Korea
- Volunteers
- 27 people
- Sponsor
- Chonbuk National University Hospital
Bipolar Disorder, Schizoaffective Disorder
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Aim: In a population of first episode manic patients with psychotic features, we want to compare the side effect profile, the degree of adherence and the subjective well being, as well as the efficacy of two treatments: The…
- Trial name
- NCT00202293
- Testing
- Olanzapine, Lithium, Chlorpromazine
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Melbourne Health
First-Episode Psychosis, Bipolar Disorder
Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI
Significant changes in brain morphology are observed in people with first-episode psychosis. Studies have shown that total brain volume and particular brain structures are decreased in people with psychosis disorders.
- Trial name
- CARB (NCT02334904)
- Testing
- Aripiprazole, Risperidone
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
First Episode Psychosis
Artificial Intelligence to Measure Adherence to Oral Medication
The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis.
- Trial name
- NCT04046497
- Testing
- Smartphone App, Usual Care
- Where
- 5 sites in United States
- Volunteers
- 139 people
- Sponsor
- Northwell Health
First Episode Psychosis (FEP), Clinical High Risk for Psychosis (CHR)
Reducing the Duration of Untreated Psychosis in the United States: The Impact of Screening and Systematic Communication
The goal of this project is to investigate whether a systematic screening approach enhanced by an innovative model of communicating information about psychosis and treatment options to patients and families (ComPsych) can reduce…
- Trial name
- EaSIE (NCT05509998)
- Testing
- Screening Method (SM), Screening and Communication Method (SCM)
- Where
- United States
- Volunteers
- 912 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Diet, Healthy, Psychotic Disorders
Weight Management Program for Patients With First Episode Psychosis
Severe mental illnesses (SMI), such as schizophrenia, are associated with increased morbidity and mortality in large part due to obesity and concomitant metabolic disorders.
- Trial name
- NCT05207982
- Testing
- Family Based weight management program
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- State University of New York at Buffalo
First-episode Psychosis, Cannabis Abuse
COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE
General objective: To assess the effectiveness of a treatment program specific for cannabis abuse (cognitive behavioral treatment + pharmacological treatment) compared to standard treatment (pharmacological treatment +…
- Trial name
- NCT02319746
- Testing
- Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse, Psychoeducation
- Where
- Spain
- Volunteers
- 88 people
- Sponsor
- Basque Health Service
Psychosis
Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis
The purpose of this study is determine the minimal effective dose and the impact on: 1. treatment outcomes at 4, 12 and/or 48 weeks the treatment has required to treat patients experiencing the first psychotic episode 2.
- Trial name
- NCT00449397
- Testing
- Quetiapine Fumarate
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Psychosis, First Episode Psychosis
Stratification and Treatment in Early Psychosis Study - ENHANCE
The purpose of this study is: To investigate whether the response to antipsychotic treatment can be enhanced by adding cannabidiol (CBD) to the existing treatment, compared to placebo, in participants with a first episode of…
- Conditions
- Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode
- Trial name
- STEP-ENHANCE (NCT06778564)
- Testing
- CBD 100 mg/mL Oral Solution
- Where
- 17 sites in Austria, Germany and 7 more
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Schizophrenia, Schizoaffective Disorder
Optimizing Response in Psychosis Study
The purpose of this project is to evaluate the efficacy of long-acting risperidone for patients with first episode schizophrenia spectrum who did not improve sufficiently with the first antipsychotic medication they tried during…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified
- Trial name
- ORP (NCT00314327)
- Testing
- long-acting injectable risperidone
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Northwell Health
Smoking, Psychosis
A Usability Study of a Smoking Cessation Decision Aid in People With a Recent First Episode of Psychosis
The investigators propose to recruit patients who have experienced a recent first episode of psychosis who have a chart diagnosis of Schizophrenia, Schizophrenifom, Schizoaffective Disorder, Psychosis NOS, or Bipolar I Disorder…
- Trial name
- NCT01399112
- Testing
- Web-based computer program
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Northwell Health
Insomnia, Psychosis
Implementation of Digital CBT for Insomnia in First Episode Psychosis
This study uses mixed methods to investigate the implementation of digital cognitive behavioural therapy for insomnia (Sleepio) in a first episode of psychosis service (FEP).
- Conditions
- Insomnia, Psychosis, First Episode Psychosis
- Trial name
- NCT05050201
- Testing
- Sleepio
- Where
- 2 sites in United Kingdom
- Volunteers
- 22 people
- Sponsor
- NHS Greater Glasgow and Clyde
Psychosis, Schizophrenia
ReMindCare App for Patients From First Episode of Psychosis Unit.
ReMindCare is an app designed by the Unit of Psychiatry at the Clinical Hospital of Valencia in liaison with the Polytechnic University of Valencia.
- Conditions
- Psychosis, Schizophrenia, Psychotic Disorders, Delirium
- Trial name
- NCT03807388
- Testing
- ReMindCare Intervention Group, Treatment as Usual
- Where
- Spain
- Volunteers
- 140 people
- Sponsor
- Instituto de Investigacion Sanitaria INCLIVA
First Episode Psychosis, Psychosis
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
Psychosis is a disabling condition that typically has its onset in adolescence and early adulthood. Many young people with psychosis have difficulty navigating services or are reluctant to engage in treatment until their illness…
- Conditions
- First Episode Psychosis, Psychosis, Psychotic Episode, Psychoses, Affective
- Trial name
- NCT04298450
- Testing
- Active SMS Intervention
- Where
- Canada
- Volunteers
- 186 people
- Sponsor
- Centre for Addiction and Mental Health
Psychosis
Narrative Identity and Its Relationship to Subjective Multidimensional Well-being in First Episode Psychosis
The transition between adolescence and adulthood (generally defined as ages 18 to 25) is a key developmental window for narrative identity and psychotic disorders. Narrative identity is positively associated with mental health.
- Trial name
- PEPsy-Identity (NCT06464848)
- Testing
- Narrative identity task
- Where
- France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
First Episode Psychosis
Early-Phase Schizophrenia: Practice-based Research to Improve Outcomes
The goal if the project is to develop a learning health network devoted to the treatment of first episode psychosis.
- Trial name
- ESPRITO (NCT04004364)
- Testing
- Coordinated Specialty Care (CSC)
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Northwell Health